IDH2 and myeloproliferative neoplasm: In a study by Pardanani et al, a total of nine IDH mutations in 78 chronic-phase MPN patients (12%) were reported including four in 25 PMF (16%), four in 39 PV (10%) and one in 14 ET patients (7%) [33].